This biological targeting of F98 glioma cells that overexpress integrins αvβ3, apart from LAT-1-targeted BPA, would provide a novel target for BNCT against high-grade gliomas with a heterogeneous nature. The gene discussed is SLC7A5; the disease is central nervous system cancer.